Aether Industries Ltd

- There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. - The company discusses ongoing expansions and capex for augmenting capabilities but does not mention raising funds specifically via debt or equity. - Focus is on operational improvements, capacity utilization, and commercial ramp-up of projects like Baker Hughes contract. - Insurance claims related to the fire accident are expected to result in inflows in Q3 FY'25, which may support cash flows. - Management aims to improve working capital cycles and operating cash flow, suggesting emphasis on internal accruals rather than external fundraising at this time.

- Ongoing capex across multiple sites to augment capabilities, focusing on chemical reaction capabilities from R&D to commercial scale (Page 5-6). - Expansion of R&D infrastructure with a 2x increase planned at the existing site by 2025 (Page 11). - Construction of Site 5 (Panoli), a greenfield expansion with 16 production blocks planned; Phase 1 expected to complete by Q3 FY 2025-26 (Pages 4, 10-11). - Commissioning of Site 3+ and 3++ expected in early Q1 FY 2025-26 (Page 4). - Enhancements and revamping of fire-affected Site 2 targeting 100% operations by mid-November 2024 (Pages 4-5). - 15 MW solar power plant installation underway, with 10 MW commissioned and remaining 5 MW expected by October 2024, supporting sustainability and operational cost savings (Page 4). - Capex supporting growth in CRAMS business and contract manufacturing, including partnerships like Baker Hughes and SEQENS Group (Pages 5-6, 10-12).

- The demand for products remains strong with volume growth seen across all three business models: large-scale manufacturing, contract/exclusive manufacturing, and CRAMS. - The company added 12 new clients in the recent quarter, indicating expanding customer base. - Contract/exclusive manufacturing revenues are expected to rise significantly from Q3 and Q4 FY25 with commercial orders from Baker Hughes starting then. - Pricing pressures from Chinese competition have kept prices low, but price correction is anticipated from Q4 FY25 or Q1 calendar year 2025, which should improve margins. - The CRAMS business model is seen as the growth engine, with expanded R&D, pilot plant capabilities, and ongoing addition of innovative customers. - Panoli Site 5 expansion with 16 production blocks will increase capacity with visibility on 40–45% of production already. - Overall, the company targets a return to EBITDA margins of around 28–30% and expects volume and revenue growth across pharmaceutical, agrochemical, renewables, and oil & gas sectors.

- Target to inch EBITDA margins back to traditional levels of around 28%-30% by second half of the year (Rohan Desai, Page 14). - Expect improvement in pricing starting Q4 FY25 / Q1 calendar year 2025, which should enhance margins (Rohan Desai, Pages 9 and 7). - PAT margin improved from 16%-17% in Q1 to 17%-18% in Q2 FY25, indicating a positive earnings trend (Page 4). - CRAMS business model seen as a significant growth engine with optimistic outlook and continuous addition of customers (Aman Desai, Page 11). - Revenue growth is expected with full operations expected at the fire-affected site by mid-November 2024 and new projects commissioning in FY26 (Pages 4 and 5). - New contract manufacturing projects, including Baker Hughes, expected to contribute significantly from Q3 FY25 onwards (Pages 12 and 10). - Working capital improvements should positively impact cash flow and earnings (Page 10).

- Aether Industries has ongoing contract/exclusive manufacturing orders, including a contract with SEQENS Group for launch and market development quantities (100 metric tons), with expectations of significantly higher commercialization volumes in the future. - The Baker Hughes contract faced delays, impacting revenue guidance for the current fiscal year, but the guidance for next year remains intact (~INR 350 crores for next year). - Multiple advanced projects in renewables, sustainability, pharma, agrochemicals, and oil and gas sectors are in advanced stages at various sites, including Site 3++ and Panoli (Site 5). - The company has visibility for 6-7 production blocks out of 16 planned in Panoli, covering both in-house molecules and contract manufacturing. - New customer additions include 12 clients this quarter, mainly in pharma, agro, coatings, and CRAMS segments, indicating ongoing orderbook expansion.